Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age

被引:67
|
作者
Beaber, Elisabeth F. [1 ,2 ,3 ]
Buist, Diana S. M. [1 ,3 ]
Barlow, William E. [4 ]
Malone, Kathleen E. [2 ,3 ]
Reed, Susan D. [1 ,2 ,3 ,5 ]
Li, Christopher I. [2 ,3 ]
机构
[1] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA
[2] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
关键词
YOUNG-WOMEN; UNITED-STATES; EPITHELIAL PROLIFERATION; HORMONAL CONTRACEPTIVES; ESTROGEN-RECEPTOR; HISTORIES; PROGESTINS; COHORT; TRENDS;
D O I
10.1158/0008-5472.CAN-13-3400
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies of oral contraceptives and breast cancer indicate that recent use slightly increases risk, but most studies relied on self-reported use and did not examine contemporary oral contraceptive formulations. This nested case-control study was among female enrollees in a large U. S. integrated health care delivery system. Cases were 1,102 women ages 20 to 49 years diagnosed with invasive breast cancer from 1990 to 2009. Controls were randomly sampled from enrollment records (n = 21,952) and matched to cases on age, year, enrollment length, and medical chart availability. Detailed oral contraceptive use information was ascertained from electronic pharmacy records and analyzed using conditional logistic regression, ORs, and 95% confidence intervals (CI). Recent oral contraceptive use (within the prior year) was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.3-1.9) relative to never or former OC use. The association was stronger for estrogen receptor-positive (ER+; OR, 1.7; 95% CI, 1.3-2.1) than estrogen receptor-negative (ER-) disease (OR, 1.2, 95% CI, 0.8-1.8), although not statistically significantly different (P = 0.15). Recent use of oral contraceptives involving high-dose estrogen (OR, 2.7; 95% CI, 1.1-6.2), ethynodiol diacetate (OR, 2.6; 95% CI, 1.4-4.7), or triphasic dosing with an average of 0.75 mg of norethindrone (OR, 3.1; 95% CI, 1.9-5.1; P-heterogeneity compared with using other oral contraceptives = 0.004) was associated with particularly elevated risks, whereas other types, including low-dose estrogen oral contraceptives, were not (OR, 1.0; 95% CI, 0.6-1.7). Our results suggest that recent use of contemporary oral contraceptives is associated with an increased breast cancer risk, which may vary by formulation. If confirmed, consideration of the breast cancer risk associated with different oral contraceptive types could impact discussions weighing recognized health benefits and potential risks. (C)2014 AACR.
引用
收藏
页码:4078 / 4089
页数:12
相关论文
共 50 条
  • [41] Trends in Mammography Use Among Women Aged 40 to 49 Years With a History of Breast Cancer
    Bensenhaver, Jessica M.
    Martinez, Angy P. Perez
    Albert, Peter G.
    Hawley, Sarah T.
    Petersen, Lindsay F.
    Newman, Lisa A.
    JAMA SURGERY, 2018, 153 (12) : 1153 - 1154
  • [42] ORAL-CONTRACEPTIVE USE AND BREAST-CANCER RISK - A METAANALYSIS OF VARIATIONS WITH AGE AT DIAGNOSIS, PARITY AND TOTAL DURATION OF ORAL-CONTRACEPTIVE USE
    RUSHTON, L
    JONES, DR
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1992, 99 (03): : 239 - 246
  • [43] Oral contraceptive use and risk of suicidal behavior among young women
    Edwards, Alexis C.
    Lonn, Sara Larsson
    Crump, Casey
    Moscicki, Eve K.
    Sundquist, Jan
    Kendler, Kenneth S.
    Sundquist, Kristina
    PSYCHOLOGICAL MEDICINE, 2022, 52 (09) : 1710 - 1717
  • [44] ORAL-CONTRACEPTIVE USE AND THE RISK OF BREAST-CANCER IN WOMEN WITH A PRIOR HISTORY OF BENIGN BREAST DISEASE
    STADEL, BV
    SCHLESSELMAN, JJ
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1986, 123 (03) : 373 - 382
  • [45] Oral contraceptive use and breast cancer risk in areas with different incidence - A case-control study among young women
    Traina, A
    Cusimano, R
    Liquori, M
    Calabria, C
    Biglia, N
    Ponzone, R
    Sgro, L
    Sismondi, P
    BASIS FOR CANCER MANAGEMENT, 1996, 784 : 564 - 569
  • [46] Breast cancer increased risk on women using combined oral contraceptive
    Fenile, R.
    Nazario, A. C. P.
    Simoes, C. M.
    CANCER RESEARCH, 2017, 77
  • [47] Breast cancer and oral contraceptive use in Asian-American women
    Ursin, G
    Wu, AH
    Hoover, RN
    West, DW
    Nomura, AMY
    Kolonel, LN
    Pike, MC
    Ziegler, RG
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1999, 150 (06) : 561 - 567
  • [48] Oral Contraceptive Use and Breast Cancer: A Prospective Study of Young Women
    Hunter, David J.
    Colditz, Graham A.
    Hankinson, Susan E.
    Malspeis, Susan
    Spiegelman, Donna
    Chen, Wendy
    Stampfer, Meir J.
    Willett, Walter C.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (10) : 2496 - 2502
  • [49] SCREENING FOR BREAST-CANCER AND MORTALITY REDUCTION AMONG WOMEN 40-49 YEARS OF AGE
    KOPANS, DB
    CANCER, 1994, 74 (01) : 311 - 322
  • [50] Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women
    Terry, MB
    Gammon, MD
    Schoenberg, JB
    Brinton, LA
    Arber, N
    Hanina, H
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1100 - 1103